hotspot -WSS

hotspot

author：entertainment 2025-09-28 21:11:19 - browse：1331

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Global cancer cases to surge 77% by 2050, WHO report says

knowledge

WSS

House GOP plan to stem drug shortages differs from Democrats’

Why Novartis is going to walk from its acquisition of MorphoSys

Europe is fastest

The CDC's new social media misinformation war

Judge orders hearing on Trump's motion to disqualify Fulton County DA

AI gets buy

explore

hotspot

Wikipedia

Sports medicine is finally prioritizing gender equality

Campaign finance charge dropped from case against Sam Bankman

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Heart attack and stroke risk calculators need revising

Bernie brings in new pharma CEOs to talk drug prices

The high cost of giving birth even with insurance

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Duchenne breakthrough therapy leaves behind pioneering families

Surgery pushed Ben Carson to fame

focus

Trump team launching legal defense fund to help pay legal bills

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Why Novartis is going to walk from its acquisition of MorphoSys

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Unique patient identifier: Experts argue the benefits, pitfalls

Teacher posts viral 'school supply rant' with advice for parents

Wikipedia

leisure time

knowledge

hotspot